Vig Mohini, Dubey Shweta
Amity Institute of Virology & Immunology, Amity University Uttar Pradesh (AUUP), Sector 125, Noida, Uttar Pradesh, India.
Amity Institute of Virology & Immunology, Amity University Uttar Pradesh (AUUP), Sector 125, Noida, Uttar Pradesh, India.
Int Rev Cell Mol Biol. 2025;394:147-170. doi: 10.1016/bs.ircmb.2024.12.014. Epub 2025 Jan 22.
Multiple innovative molecular techniques have established compelling connections between the gut microbiome and cancers. Studies have also revealed that the microbiome and microbiome-specific metabolites can significantly influence cancer treatments like chemotherapy, radiotherapy, and immunotherapy. Advancements in cancer immunotherapy driven by a targeted immune system approach have considerably improved the treatment landscape in cancer. However, the full potential of tumor immunotherapy remains to be explored, and many challenges need to be addressed. This review provides a summary of the current evidence regarding the presence of microbiota and how it can impact the response to Food and Drug Administration (FDA) approved cancer immunotherapies, such as immune checkpoint inhibitors (ICIs) or chimeric antigen receptor T (CAR-T) cell therapy. Additionally, it addresses the challenges and limitations of gut microbiome and cancer immunotherapy.
多种创新分子技术已在肠道微生物群与癌症之间建立了令人信服的联系。研究还表明，微生物群和微生物群特异性代谢产物可显著影响化疗、放疗和免疫治疗等癌症治疗方法。以靶向免疫系统方法驱动的癌症免疫治疗进展极大地改善了癌症治疗格局。然而，肿瘤免疫治疗的全部潜力仍有待探索，许多挑战需要解决。本综述总结了关于微生物群存在的当前证据，以及它如何影响对美国食品药品监督管理局（FDA）批准的癌症免疫治疗的反应，如免疫检查点抑制剂（ICIs）或嵌合抗原受体T（CAR-T）细胞疗法。此外，它还探讨了肠道微生物群与癌症免疫治疗的挑战和局限性。
